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Peptide immunotherapy for Type 1 
Diabetes—Clinical Advances
Emma L. Smith1* and Mark Peakman2
1 UCB Pharma Ltd., Slough, United Kingdom, 2 Department of Immunobiology, King’s College London, London,  
United Kingdom
Autoimmune and allergic diseases occur when an individual mounts an inappropriate 
immune response to a self-antigen or an innocuous environmental antigen. This triggers 
a pathogenic T-cell response resulting in damage to specific tissues and organs. In type 
1 diabetes (T1D), this manifests as destruction of the insulin-secreting β cells, resulting 
in a life-long dependency on recombinant insulin. Modulation of the pathogenic T-cell 
response with antigen-specific peptide immunotherapy offers the potential to restore the 
immune homeostasis and prevent further tissue destruction. Recent clinical advances 
with peptide therapy approaches in both T1D and other diseases are beginning to show 
encouraging results. New technologies targeting the peptides to specific cell types are 
also moving from pre-clinical development to the clinic. While many challenges remain in 
clinical development, not least selection of the optimal dose and dosing frequency, this 
is clearly becoming a very active field of drug development.
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inTRODUCTiOn
Type 1 diabetes (T1D) is an organ-specific autoimmune disease. Auto-reactive T cells attack the 
insulin-producing beta (β) cells of the pancreatic islets, leading to a loss of endogenous insulin 
production and subsequent impaired glucose metabolism. Management of the disease requires daily 
administration of exogenous insulin and frequent monitoring of blood glucose levels. While there 
have been significant advances in recombinant human insulins and technologies both to deliver 
insulin and monitor blood glucose levels, many patients do not achieve optimal glycemic control. 
This is particularly apparent in children and young adults, in whom blood glucose control, measured 
by glycated hemoglobin (HbA1c) levels, is typically poor, reaching greater than 8% in the majority 
when the desired levels are below 7.5% (1). The longer-term complications associated with elevated 
levels of HbA1c are significant and include retinopathy, nephropathy, and neuropathy. Clearly, there 
is a need for new therapies that either preserve or restore β-cell function to improve glycemic control 
and patient outcomes.
Preservation of an individual’s own endogenous insulin secretion by modulation of the immune 
system would be the optimal solution. However, the major challenge for this therapeutic 
approach is that at the time of diagnosis, a considerable loss of β cells has already occurred (2). 
Encouragingly, there are now supportive data to suggest that preservation of residual β-cell 
function at the time of diagnosis may indeed lead to improvements in glycemic control (3, 4) 
and thereby impact upon long-term outcomes. Preventing immune-mediated attack on β cells 
would also open the possibility for β-cell regeneration and/or replacement therapies to be more 
effective and durable.
FiGURe 1 | Peptide therapy restores immune homeostasis via natural antigen-specific immunoregulatory pathways. Highly soluble peptides are taken up by 
immature dendritic cells and presented to antigen-specific CD4+ T cells. The CD4+ T cells have one of the three potential fates; death, anergy, or the expansion/
generation of a regulatory T-cell phenotype. The regulatory T cells suppress the pathogenic T cell via IL-10 secretion. Each peptide has the capacity to induce a 
different population of regulatory T cells.
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PePTiDe iMMUnOTHeRAPY
Autoimmune and allergic diseases arise when an individual 
mounts an inappropriate immunological response to a self-
antigen or an innocuous environmental antigen (5). Antigen-
reactive T  cells become activated and expand in number, and 
the regulatory T-cell pool is no longer capable of controlling the 
immune response, leading to the loss of immune homeostasis. 
Peptide immunotherapy offers the potential to restore immune 
homeostasis via the expansion of the regulatory T-cell pool and 
the deletion and/or anergy of the pathogenic T-cell population 
(Figure 1).
Clinical proof of concept that peptide therapy can restore 
immune homeostasis has been championed by studies of allergic 
disease. Cat-PAD is a peptide cocktail consisting of seven peptides 
from Feld1, the major cat allergen. A recent clinical study has shown 
that a short course of intra-dermal treatment with these peptides 
resulted in a clinically meaningful reduction in rhino-conjunctivi-
tis symptoms, 2 years post-treatment (6). Disappointingly, a large 
phase III study failed to confirm the earlier positive clinical data 
(ClinicalTrials.gov: NCT01620762). This may in part be explained 
by a large placebo effect that was observed and the transition to 
field-based studies, which inherently introduce greater variability. 
An ongoing clinical study focusing on the phenotype of the 
allergen-specific T cells following administration of Cat-PAD will 
confirm whether peptide therapy can modulate the pathogenic 
T-cell response (ClinicalTrials.gov: NCT02311413).
Clinical studies with peptides derived from auto-antigens for 
the treatment of autoimmune disease are also now emerging. 
A phase IIa study with a peptide immunotherapy treatment for 
relapsing remitting multiple sclerosis demonstrated statistically 
significant reductions in total and new T1 Gadolinium enhancing 
brain lesions (representing sites of inflammation and damage) 
measured using magnetic resonance imaging during treatment. 
This therapy consists of a cocktail of four peptides derived from 
myelin basic protein.1 Two recent phase I studies with a peptide 
immunotherapy treatment for celiac disease have also shown 
encouraging data suggesting that the antigen-specific T-cell 
responses can be modulated following peptide treatment (7). 
Further development of NexVax2, a mix of three peptides derived 
from gluten, is planned.
PePTiDe iMMUnOTHeRAPY FOR T1D
For peptide therapy to be successful in treating autoimmune 
or allergic disease, it is essential that the major auto-antigens 
responsible for driving the disease are known. Using the pres-
ence of auto-antibodies to the same antigens as a guide increases 
the probability that appropriate antigens have been selected. The 
ability to detect antigen-specific T cells is also important not only 
to aid the initial epitope discovery of disease-relevant peptides 
but also to track modulation of the T-cell phenotype following 
clinical administration.
Type 1 diabetes emerges as an ideal autoimmune disease for 
trialing treatment with peptide therapy. A number of the major 
antigens have been identified, including proinsulin, GAD65, IA-2, 
and ZnT8. Auto-antibodies to these antigens can be detected both 
in the sera of patients at the time of diagnosis and in individuals 
who are at high risk of future disease, whether they are entirely 
1 https://apitope.com/apitope-announces-positive-atx-ms-1467-phase-iia-data-
relapsing-multiple-sclerosis/
FiGURe 2 | Peptide therapy for type 1 diabetes (T1D) offers the opportunity to halt further progression of disease in newly diagnosed individuals and to prevent 
clinical symptoms of disease in at-risk individuals. T1D is a T-cell-mediated autoimmune disease characterized by the destruction of the pancreatic β cells, resulting 
in a decrease in insulin secretion (measured via c-peptide). Genetic factors have been identified as contributing to the risk of developing T1D as well as certain 
environmental factors. Prior to the clinical symptoms of T1D, auto-antibodies to one or more islet cell antibodies are detected and individuals become dysglycaemic. 
Current intervention with peptide therapy is focused on treating newly diagnosed patients. Future invention studies aim to treat individuals prior to clinical diagnosis 
in the prevention setting.
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asymptomatic with no signs of disease, or have early indications 
of impaired glucose tolerance (8). Antigen-specific T cells from 
the blood of patients and at-risk subjects can be detected and, 
indeed, exhibit a proinflammatory cytokine response upon 
antigen stimulation ex vivo (9, 10). It is appealing to propose that 
progression of disease toward diabetes in high-risk subjects will 
be more tractable to therapies such as peptide administration than 
the scenario of waiting for the disease to become established. In 
the future, this will need to be tested in multiple antibody-positive 
non-diabetic subjects, whose risk of disease development over a 
lifetime approaches 100% (Figure 2).
An early clinical study in T1D patients administered an altered 
peptide ligand (APL) derived from the insulin B9-23 epitope 
(NBI-6024) showed some initial promise (11). Modulation of 
the antigen-specific T-cell response from a predominantly IFNγ 
response to a more Th2 bias was detected. However, a subsequent 
clinical study powered to assess the effect of repeated administra-
tions of NBI-6024 on endogenous insulin production, as meas-
ured by C-peptide levels in adult and adolescent patients with 
new-onset T1D, failed to demonstrate any clinical benefit (12).
In parallel to the clinical development of NBI-6024, a natural 
peptide sequence derived from proinsulin was also under evalua-
tion. An initial phase 1 safety study in patients with long-standing 
diabetes and low c-peptide levels (<200 pmol/L) compared three 
monthly intra-dermal injections of 10 versus 100 µg of the C19-
A3 peptide (13). The peptide was shown to be well tolerated and 
safe. In addition, as was observed in the initial NBI-6024 study, 
there was a trend toward modulation of the antigen-specific 
T-cell response with an apparently increased frequency of IL-10 
producing cells in the low-dose treatment group.
Subsequently, a second clinical study with the single proinsu-
lin peptide was conducted in newly diagnosed patients and the 
results have recently been reported (14). In this study, monthly 
versus fortnightly intra-dermal injections of 10 µg of peptide were 
compared, over a period of 6 months. The peptide was shown to 
be well tolerated and safe. Although the study was not powered 
to examine efficacy at the level of preservation of β-cell function, 
there was evidence in some patients on the active treatment that 
the rate of decline in secreted c-peptide slowed and daily insulin 
use and HbA1c stabilized. Intriguingly, these subjects who could 
be labeled “treated c-peptide responders” also showed immuno-
logical changes compared with non-responders on active treat-
ment, including greater propensity for CD4 T-cell production of 
IL-10 upon ex vivo stimulation and enhanced expression of the 
canonical regulatory T cell transcription factor FoxP3 on periph-
erally generated, adaptive regulatory T cells post-therapy. These 
findings, linking clinical and immunological outcome provide an 
encouraging platform on which to build strategies for biomarkers 
of peptide immunotherapy.
The clinical studies described thus far, both in T1D and the 
other indications, have focused on either a single peptide to 
modulate the pathogenic T  cell response or multiple peptides 
from the same antigen. A different approach, using multiple pep-
tides from two different auto-antigens linked to the pathogenesis 
of T1D, is currently being evaluated as a treatment for new-onset 
T1D patients (ClinicalTrials.gov: NCT02620332). This phase Ib 
tolerability and safety study evaluating monthly intra-dermal 
injections of a cocktail of multiple peptides should provide new 
insights when data become available in 2018.
A slightly different peptide therapy approach to those previ-
ously described is also under clinical evaluation. The approach 
is to take a natural peptide derived from one of the major auto-
antigens linked to T1D and modify it slightly to improve its 
affinity (15). These modified peptides are known as Imotopes™. 
4Smith  and Peakman Peptide Immunotherapy in T1D
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Injection of the Imotopes™ is believed to elicit antigen-specific 
cytolytic CD4 T  cells that induce lysis of antigen-presenting 
cells (APCs) with which a synapse is formed, as well as the auto-
antigen-specific bystander T cells, activated on the surface of the 
same APC. A phase Ib safety and tolerability study is currently 
underway, exploring three different doses administered sub-
cutaneously in alum, with study completion expected December 
2018 (ClinicalTrials.gov: NCT03272269).
PROMiSinG PRe-CLiniCAL PePTiDe 
THeRAPY APPROACHeS
The peptide therapy approaches leading the way in clinical devel-
opment for both T1D and other autoimmune diseases are rela-
tively simple. The peptides are administered either intra-dermally 
or sub-cutaneously in the absence of any additional substantial 
modifications. Whether these approaches are sufficient to bring 
significant clinical benefit in large phase III clinical studies remains 
to be seen, but certainly, the promise peptide therapy holds for 
restoration of immune regulation has led a number of pharma-
ceutical companies to develop novel and innovative ways to target 
the peptides in a more specific manner for potentially enhanced 
efficacy. These include targeting of peptides to the erythrocyte 
(16), encapsulating peptides into nanoparticles (17–19) and 
encapsulating peptides into liposomes with α-GalCer.2 A highly 
novel approach being developed involves coating peptide-MHC 
complexes onto nanoparticles to generate “navacims” (20). As yet, 
there are no data to indicate which method of peptide delivery 
will be optimal and bring the greatest clinical benefit, but clearly 
this is a fast evolving field.
FUTURe CHALLenGeS  
AnD OPPORTUniTieS
While peptide therapy for T1D is clearly entering an exciting 
phase of drug development, there are still a number of unanswered 
questions and challenges, not least whether the approach will 
bring real clinical benefit. Selecting the optimal dose of peptide 
and optimal dosing interval is one key challenge. This is in part 
because it is difficult to study both the kinetics of peptide uptake 
and the bio-distribution of peptides. Access to better immuno-
logical tools to track the antigen-specific T cells will undoubtedly 
help our understanding; this includes further development of both 
tetramers and ex vivo assays that selectively stimulate antigen-
specific cells (21). The ability to sample T cells at the site of active 
disease and/or site of peptide administration may also provide 
greater insight into the mechanism of action of peptide therapy. It 
is generally believed that peptide therapy induces a population of 
IL-10 secreting regulatory T cells. However, this is primarily based 
on in vivo data from mouse studies that have clearly demonstrated 
expansion of an IL-10 secreting, regulatory T-cell population fol-
lowing sub-cutaneous administration of peptide (22). Translation 
of this mechanism into the clinical setting is still to be proven and 
may well depend on the route of administration of the peptides. 
Nonetheless, as discussed earlier, circulating IL-10 producing, 
2 http://www.regimmune.com/product-pipeline/tid/
antigen-specific CD4 T  cells have been observed post-intra-
dermal peptide administration in studies in T1D patients and this 
mode of action remains a major focus of attention.
Once the technologies and assays have been further refined 
so that tracking of antigen-specific T cells, both pathogenic and 
regulatory, can be accomplished, additional questions can start 
to be addressed. Importantly, degrees of clinical efficacy can 
begin to be correlated with both the frequency of regulatory 
T-cell expansion and the phenotype of the expanded regulatory 
T  cells. Is better efficacy achieved via the generation of IL-10 
producing regulatory T cells, the Foxp3+ regulatory T cell, or a 
combination of both? It will also be important to understand the 
longevity of the effect and whether this is dependent on the phe-
notype of the regulatory T cell. It may be that the different routes 
of administration of peptides and the newly emerging targeted 
technologies mentioned previously lead to the generation of dif-
ferent populations of regulatory T cells. It is not inconceivable to 
think that different diseases may be better treated by induction 
of one particular population of regulatory T cell versus another. 
In addition, different stages of progression within the same disease 
may be more amenable to treatment by one subset of regulatory 
T  cell over another. This may be particularly true for diseases 
where there is significant epitope spreading. In this situation, one 
might envisage early in disease using a peptide treatment that 
induces the Foxp3+ regulatory T  cell and later in the disease 
pathogenesis, using a peptide treatment that induces the IL-10 
secreting regulatory T cell.
One must also acknowledge that administration of peptide 
therapy alone may not be sufficient to prevent disease in an 
inflammatory setting. In this setting, the peptide therapy may 
indeed be inducing a population of regulatory T  cells, but the 
inflammatory environment may also be driving a pathogenic 
T-cell population, which is not adequately suppressed by the 
regulatory cells. Therapies that directly inhibit the pathogenic 
T cell while sparing the regulatory T cell would be optimal under 
these circumstances. These could include therapies that target 
the APC to prevent full activation, achieved for example using 
antibodies against CD40. Alternatively, therapies that inhibit 
effector T-cell function directly could be beneficial. This could be 
achieved either via inhibition of T-cell co-stimulatory receptors 
such as CD40L, OX40, and ICOS or via engagement of negative 
regulators such as PD-1 and TIGIT. Modulation of the cytokine 
milieu may also synergize with the efficacy of peptide therapy. 
This could be achieved via direct inhibition of the proinflamma-
tory cytokines secreted by the pathogenic T cell or inhibition of 
cytokines responsible for maturation of the APC.
While the challenges are undoubtedly there, peptide therapy 
does offer a significant opportunity to restore immune regulation 
in T1D and other autoimmune diseases. Further clinical stud-
ies and technological advances will hopefully translate peptide 
therapy into a safe, effective, and highly specific novel class of 
therapeutics.
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